<h2 class="mt-4 text-lg font-medium text-color-lightgreytext" data-astro-cid-fjd3bvuv>
Summary from the AllSides News Team
</h2> <div class="mt-2 text-md editor-content" data-astro-cid-fjd3bvuv><p>The Food and Drug Administration on Monday approved a drug to treat patients with Alzheimer’s disease for the first time since 2003. Some experts have voiced concerns over conflicting evidence of the drug’s effectiveness, which <a href="https://www.nytimes.com/2020/11/06/health/aducanumab-alzheimers-drug-fda-panel.html" target="_blank" rel="noopener noreferrer">prompted the FDA’s independent advisory committee to oppose approval</a> in November 2020. Biogen, the drug’s developer, will be required to conduct a post-approval confirmatory trial to verify&nbsp;the drug's cognitive benefits. The drug, named aducanumab and branded Aduhelm, could be pulled from the market if no benefits are found.</p>

<p>Coverage was more widespread in center- and left-rated outlets as of Monday afternoon. Some coverage from across the spectrum focused on the efficacy debate, with other coverage&nbsp;focusing on the 20-year gap.</p>
</div> <h2 class="mb-2 leading-6 text-lg text-gray-500 font-medium mt-4 p-0">
Featured Coverage of this Story
</h2> <div class="flex gap-5 my-2 mb-8 md:flex-row flex-col"> <div class="flex-1 left"><div class="mb-2 font-bold border-solid global-bias-label text-color-left border-b-[3px] text-s border-color-left">From the Left</div><a id="News-Item--f-d-a-approves-alzheimer-s-drug-despite-fierce-debate-over-whether-it-works" href="https://www.nytimes.com/2021/06/07/health/fda-approves-alzheimers-drug.html" target="_blank" rel="noopener"><div class="m-0 font-bold leading-tight text-md hover:underline text-base">F.D.A. Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works</div></a><div class="flex gap-2 items-center pt-2 hover:underline"><div class="overflow-hidden whitespace-nowrap"><p class="text-xs">New York Times (News)</p></div><img src="https://img.allsides.com/sites/default/files/bias-leaning-left.png" alt="AllSides Media Bias Rating: Lean Left" title="AllSides Media Bias Rating: Lean Left" width="72" height="12" class="news-source-bias-image shrink-0" style="width: 72px !important; height: 12px !important; max-width: 72px !important;"><div class="flex-1 text-right ml-2 text-xs text-gray-500 underline whitespace-nowrap">
See rating details
</div></div><div class="mt-4"><div class="relative w-full"><img src="https://img.allsides.com/sites/default/files/merlin_188441217_f0aeeda4-2c6b-4232-bebd-592599e9f0f5-jumbo.jpg" alt="F.D.A. Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works" class="w-full h-auto object-cover"><div class="absolute bottom-0 left-0 right-0 h-12 bg-gradient-to-b from-color-transparent via-color-black/70 to-color-black px-1 pb-0 text-color-white flex items-end"><p class="text-xs pb-0.5">New York Times (News)</p></div></div></div><div class="mt-4"><div class="block text-xs leading-none mb-1 text-color-lightgreytext uppercase align-middle">News</div><div class="[&>p]:my-2 text-sm editor-content"><p>The Food and Drug Administration on Monday&nbsp;approved the first new medication for Alzheimer’s disease&nbsp;in nearly two decades,&nbsp;a contentious decision, made despite opposition from the agency’s independent advisory committee and some Alzheimer’s experts who said there was not enough evidence that the drug can help patients.</p><p>The drug, aducanumab, which will go by the brand name Aduhelm, is a monthly intravenous infusion intended to slow cognitive decline in people, with mild memory and thinking problems. It is the first approved treatment to attack the disease process of Alzheimer’s instead of just...</div><a id="Open-On--new-york-times-news-" class="text-xs inline-block border-b border-color-transparent no-underline font-bold whitespace-nowrap" href="https://www.nytimes.com/2021/06/07/health/fda-approves-alzheimers-drug.html" target="_blank" rel="noopener">
Open on New York Times (News)<i class="fa-regular fa-arrow-up-right-from-square ml-2"></i></a><div class="flex-1 whitespace-nowrap text-gray-500 text-xs leading-4 flex mt-2"><div class="hover:cursor-help" data-tippy-content="<p><span style=&#34;white-space: nowrap;&#34;>Some content from this outlet may be</span><br><span style=&#34;white-space: nowrap;&#34;>limited or behind a paywall.</span></p>"><i class="fa-regular fa-sack-dollar mr-1"></i><span class="whitespace-nowrap">Possible Paywall</span></div></div></div></div><script type="f70c78b507359a7c46cab5b6-module" src="/_astro/story-related-news.astro_astro_type_script_index_0_lang.DjPUAy8u.js"></script><div class="flex-1 right"><div class="mb-2 font-bold border-solid global-bias-label text-color-right border-b-[3px] text-s border-color-right">From the Right</div><a id="News-Item--fda-approves-biogen-s-alzheimer-s-drug" href="https://www.foxbusiness.com/lifestyle/fda-approves-biogens-alzheimers-drug" target="_blank" rel="noopener"><div class="m-0 font-bold leading-tight text-md hover:underline text-base">FDA approves Biogen’s Alzheimer’s drug</div></a><div class="flex gap-2 items-center pt-2 hover:underline"><div class="overflow-hidden whitespace-nowrap"><p class="text-xs">Fox Business</p></div><img src="https://img.allsides.com/sites/default/files/bias-leaning-right.png" alt="AllSides Media Bias Rating: Lean Right" title="AllSides Media Bias Rating: Lean Right" width="72" height="12" class="news-source-bias-image shrink-0" style="width: 72px !important; height: 12px !important; max-width: 72px !important;"><div class="flex-1 text-right ml-2 text-xs text-gray-500 underline whitespace-nowrap">
See rating details
</div></div><div class="mt-4"><div class="relative w-full"><img src="https://img.allsides.com/sites/default/files/Biogen-fda.jpg" alt="FDA approves Biogen’s Alzheimer’s drug" class="w-full h-auto object-cover"><div class="absolute bottom-0 left-0 right-0 h-12 bg-gradient-to-b from-color-transparent via-color-black/70 to-color-black px-1 pb-0 text-color-white flex items-end"><p class="text-xs pb-0.5">Fox Business</p></div></div></div><div class="mt-4"><div class="block text-xs leading-none mb-1 text-color-lightgreytext uppercase align-middle">News</div><div class="[&>p]:my-2 text-sm editor-content"><p>The Food and Drug Administration (FDA) on Monday approved Biogen’s&nbsp;Alzheimer’s drug,&nbsp;marking the first new authorized therapy to treat the disease in nearly two decades. The drug, Aduhelm (aducanumab), had received mixed reviews following earlier clinical trials.</p><p>In a statement following the approval, Dr. Patrizia Cavazzoni, director of the FDA Center for Drug Evaluation and Research, said the agency used the Accelerated Approval pathway, which is when the FDA "approves a drug for a serious or life-threatening illness that may provide meaningful therapeutic benefit over existing treatments when the drug is...</div><a id="Open-On--fox-business" class="text-xs inline-block border-b border-color-transparent no-underline font-bold whitespace-nowrap" href="https://www.foxbusiness.com/lifestyle/fda-approves-biogens-alzheimers-drug" target="_blank" rel="noopener">
Open on Fox Business<i class="fa-regular fa-arrow-up-right-from-square ml-2"></i></a></div></div><div class="flex-1 center"><div class="mb-2 font-bold border-solid global-bias-label text-color-center border-b-[3px] text-s border-color-center">From the Center</div><a id="News-Item--first-new-alzheimer-s-drug-in-nearly-two-decades-is-approved-by-fda" href="https://www.wsj.com/articles/first-alzheimers-drug-to-slow-disease-is-approved-by-fda-11623078912?mod=hp_lead_pos1" target="_blank" rel="noopener"><div class="m-0 font-bold leading-tight text-md hover:underline text-base">First New Alzheimer’s Drug in Nearly Two Decades Is Approved by FDA</div></a><div class="flex gap-2 items-center pt-2 hover:underline"><div class="overflow-hidden whitespace-nowrap"><p class="text-xs">Wall Street Journal (News)</p></div><img src="https://img.allsides.com/sites/default/files/bias-center.png" alt="AllSides Media Bias Rating: Center" title="AllSides Media Bias Rating: Center" width="72" height="12" class="news-source-bias-image shrink-0" style="width: 72px !important; height: 12px !important; max-width: 72px !important;"><div class="flex-1 text-right ml-2 text-xs text-gray-500 underline whitespace-nowrap">
See rating details
</div></div><div class="mt-4"><div class="relative w-full"><img src="https://img.allsides.com/sites/default/files/im-348340.jpg" alt="First New Alzheimer’s Drug in Nearly Two Decades Is Approved by FDA" class="w-full h-auto object-cover"><div class="absolute bottom-0 left-0 right-0 h-12 bg-gradient-to-b from-color-transparent via-color-black/70 to-color-black px-1 pb-0 text-color-white flex items-end"><p class="text-xs pb-0.5">Wall Street Journal (News)</p></div></div></div><div class="mt-4"><div class="block text-xs leading-none mb-1 text-color-lightgreytext uppercase align-middle">News</div><div class="[&>p]:my-2 text-sm editor-content"><p>The first drug promising to slow the memory-robbing march of Alzheimer’s disease was approved by U.S. health regulators, a watershed after&nbsp;years of research&nbsp;and billions of dollars in investment.</p><p>The U.S. Food and Drug Administration said it approved the drug, which has the molecular name aducanumab and will be sold as Aduhelm, based on evidence it reduces a sticky substance in the brain called amyloid that is associated with Alzheimer’s.</p><p>The drug’s sale offers hope to millions of people dealing with Alzheimer’s and their caregivers, given the lack of good options...</div><a id="Open-On--wall-street-journal-news-" class="text-xs inline-block border-b border-color-transparent no-underline font-bold whitespace-nowrap" href="https://www.wsj.com/articles/first-alzheimers-drug-to-slow-disease-is-approved-by-fda-11623078912?mod=hp_lead_pos1" target="_blank" rel="noopener">
Open on Wall Street Journal (News)<i class="fa-regular fa-arrow-up-right-from-square ml-2"></i></a><div class="flex-1 whitespace-nowrap text-gray-500 text-xs leading-4 flex mt-2"><div class="hover:cursor-help" data-tippy-content="<p><span style=&#34;white-space: nowrap;&#34;>Some content from this outlet may be</span><br><span style=&#34;white-space: nowrap;&#34;>limited or behind a paywall.</span></p>"><i class="fa-regular fa-sack-dollar mr-1"></i><span class="whitespace-nowrap">Possible Paywall</span></div></div></div></div> </div> <p class="mt-2 mb-5 text-right"> <a id="More-headline-roundups" class="group relative pr-5 hover:no-underline border-b border-opacity-0 hover:border-opacity-100 border-color-text inline-block w-fit cursor-pointer text-sm no-underline" href="/headline-roundups">